This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
FGF13 / Fibroblast growth factor 13 · Western blot design guide
Design a Western Blot for FGF13
Source-linked FGF13 Western blot protocol options, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-FGF13 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use
FGF13 Western Blot Experimental Design Guide
Expected bands, source-linked protocol options, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | ~27.6 kDa | |
| Gel | 12–15% (standard starting point) | |
| Negative control | Suggested KO / knockdown lysate |
Important caveats
Reasons your observed band may differ from the expected size.
| PTM | Phosphorylated | |
| Caveat | Phosphorylation-state controls | |
| Gene-set association | MSigDB Hallmark membership | |
| Isoform | 5 isoform(s) |
Section 1
Source-Linked FGF13 Western Blot Protocol Options
The A04991 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | extracts of various cell lines, (catalog A04991) |
| Gel % | 12–15% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Short semi-dry transfer; verify retention (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | Blocking buffer: 3% nonfat dry milk in TBST (catalog A04991) |
| Primary antibody | A04991 · 1:1000 (catalog A04991) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Goat Anti-Rabbit IgG, 1:10000 (catalog A04991) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL (catalog A04991) |
Section 2
What Is the Expected FGF13 Western Blot Band Size?
FGF13 has a predicted mass of 27.6 kDa; five isoforms could affect migration, but no empirical band size or distinct isoform pattern is supplied.
| Band near 27.6 kDa | Consistent with the predicted FGF13 mass; confirm identity with a control. |
| Several bands at different positions | Could reflect FGF13 isoforms 1–5; their migration has not been established. |
| Single band away from 27.6 kDa | Could represent an isoform or an unrelated band; its identity needs confirmation. |
| Little or no band in a nucleus-depleted lysate | Nuclear isoform 1 may be missed by this preparation. |
💡Expected FGF13 appearanceThe predicted FGF13 mass is 27.6 kDa, but no empirical band size or isoform migration is supplied; confirm a candidate band with an FGF13-specific identity control.
| Predicted FGF13 mass | Provides a 27.6 kDa reference for band assessment. |
| Isoforms 1 and 2 | Their apparent sizes may differ; individual masses are not supplied. |
| Isoforms 3 and 4 | Their apparent sizes may differ; individual masses are not supplied. |
| Isoform 5 | Its apparent size relative to the other isoforms is unknown. |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | The preparation may exclude nuclei, where isoform 1 is located. | Check a whole-cell or nuclear preparation and include an expression control. |
| Band higher than expected | Isoform identity is unresolved; a higher-migrating band is not established for FGF13. | Compare an FGF13-depleted sample and an appropriate positive control. |
| Band lower than expected | Isoform identity is unresolved; a lower-migrating band is not established for FGF13. | Compare an FGF13-depleted sample and an appropriate positive control. |
| Multiple bands | FGF13 has five named isoforms, though distinct bands are not established. | Use FGF13 depletion and isoform-aware controls to identify the bands. |
| Weak or no signal | Nuclear isoform 1 may be underrepresented in the sampled fraction. | Check nuclear recovery and compare with a positive control. |
Experiment evidence
Western blot images showing FGF13 band
A04991 · FGF13
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for FGF13 Western blot
🧪For positive controls for FGF13 in Western blot, you can use a validated FGF13-positive sample once identified, since the supplied HPA evidence names none.
Positive control: No high/medium HPA tissue identified
Negative control: Suggested KO / knockdown lysate
Loading controls: Run GAPDH, β-actin, and a total-protein stain such as Ponceau alongside the samples.
⚠️Feasibility: HPA provides no tissue data, so a positive sample needs independent validation and knockdown or KO can provide a negative control.
HPA tissue expression evidence for FGF13
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No high/medium HPA tissues identified in the supplied evidence. | ||||
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No lower-expression tissue rows available in the supplied evidence. | ||||
Section 3
Advanced FGF13 Western Blot Tips
Deeper troubleshooting and optimisation questions for FGF13, answered from its protein features.
How should FGF13 band migration be interpreted?
Band shift · Use the separately labelled calculated mass and catalog-observed evidence above. A sequence annotation does not establish an observed migration shift. Verify target identity with orthogonal controls.
Could FGF13 isoforms produce different bands?
Isoforms · Yes. Isoforms 2–5 replace canonical residues 1–62 with different N-terminal sequences. Their calculated masses may differ. Check which isoforms the antibody recognizes before assigning multiple bands.
Choose an epitope in the shared sequence after the alternatively replaced canonical residues 1–62, then verify the antibody’s stated isoform coverage. An epitope within residues 1–62 may miss isoforms 2–5.
Choose an epitope in the shared sequence after the alternatively replaced canonical residues 1–62, then verify the antibody’s stated isoform coverage. An epitope within residues 1–62 may miss isoforms 2–5.
Where is the listed FGF13 phosphorylation site?
PTM · UniProt lists phosphoserine at position 208 in canonical numbering. Check the antibody’s numbering convention when comparing sites across isoforms. The feature does not show whether phosphorylation changes migration.
Does this guide establish induction of FGF13?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
How should transfer be checked for FGF13?
Transfer · Standard workflow guidance: verify transfer efficiency for the intended target size before interpreting a weak signal. Use total-protein assessment and optimize transfer for the membrane, gel and apparatus; the labelled catalog values take precedence.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the A04991 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How should FGF13 bands be quantified across samples?
Quantitation · Use the same sample fraction and an antibody with known isoform coverage across samples. Quantify a defined band or set of bands consistently, since the five isoforms may contribute differently to the signal.
Should FGF13 migrate at exactly 27.6 kDa?
Interpretation · 27.6 kDa is the predicted mass; no observed band position is supplied. FGF13 has five isoforms with different N-terminal sequences, so identify the isoform before comparing a band with this value. The listed phosphorylation site alone does not establish a visible shift.
UniProt places isoform 1 in the nucleus. Record whether the sample is a nuclear fraction or whole-cell lysate when comparing bands; the supplied location does not establish where every isoform appears.
First check whether its size and antibody epitope are consistent with one of the five isoforms, particularly their alternative N termini. FGF13 also has a listed phosphoserine at canonical position 208, but that feature alone cannot identify or explain a shifted band.
UniProt places isoform 1 in the nucleus. Record whether the sample is a nuclear fraction or whole-cell lysate when comparing bands; the supplied location does not establish where every isoform appears.
First check whether its size and antibody epitope are consistent with one of the five isoforms, particularly their alternative N termini. FGF13 also has a listed phosphoserine at canonical position 208, but that feature alone cannot identify or explain a shifted band.
Boster reagents
FGF13 Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-Fibroblast growth factor 13 FGF13 Antibody
Cat # A04991
the supplier A04991 is an anti-FGF13 antibody listed for human, mouse, and rat reactivity. Its Western blot image uses extracts from various cell lines at 1:1000 dilution, with 25 µg protein per lane. The caption does not identify the cell lines.
Which to pick: A04991 is the only listed FGF13 antibody and has a Western blot image. Check its listed reactivity against your sample species; the image caption does not identify the tested cell lines.
Source: BosterBio FGF13 gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry Q92913.
- Human Protein Atlas. FGF13 tissue expression.
- PMC13336967 — target-verified WB comparison
- PMC11042350 — target-verified WB comparison
- PMC11709433 — target-verified WB comparison